{
    "title": "Pharmacogenetic Factors Influence Escitalopram Pharmacokinetics and Adverse Events in Youth with a Family History of Bipolar Disorder: A Preliminary Study",
    "pmid": "38377518",
    "pmcid": "PMC10880264",
    "study_parameters": [
        {
            "Study Parameters ID": 1452390397,
            "Variant Annotation ID": 1452390389,
            "Study Type": null,
            "Study Cases": 64.0,
            "Study Controls": null,
            "Characteristics": "Outpatient youth aged 12-17 years who had at least one first-degree relative with bipolar I disorder; TEASAP subscale Akathisia, hyperkinesis and somatic anxiety",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.017",
            "Ratio Stat Type": null,
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Multiple groups, Non-Hispanic Caucasian n=44, Hispanic Caucasian n=7, Black or African n = 7, Multiple or other n=8",
            "Variant Annotation ID_norm": "1452390389"
        },
        {
            "Study Parameters ID": 1452390309,
            "Variant Annotation ID": 1452390301,
            "Study Type": null,
            "Study Cases": 66.0,
            "Study Controls": null,
            "Characteristics": "Outpatient youth aged 12-17 years who had at least one first-degree relative with bipolar I disorder; TEASAP subscale Self-injury, suicidality and harm to others",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.09",
            "Ratio Stat Type": null,
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Multiple groups, Non-Hispanic Caucasian n=44, Hispanic Caucasian n=7, Black or African n = 7, Multiple or other n=8",
            "Variant Annotation ID_norm": "1452390301"
        },
        {
            "Study Parameters ID": 1452390361,
            "Variant Annotation ID": 1452390352,
            "Study Type": null,
            "Study Cases": 66.0,
            "Study Controls": null,
            "Characteristics": "Outpatient youth aged 12-17 years who had at least one first-degree relative with bipolar I disorder; TEASAP subscale Self-injury, suicidality and harm to others",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.017",
            "Ratio Stat Type": null,
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Multiple groups, Non-Hispanic Caucasian n=44, Hispanic Caucasian n=7, Black or African n = 7, Multiple or other n=8",
            "Variant Annotation ID_norm": "1452390352"
        },
        {
            "Study Parameters ID": 1452390351,
            "Variant Annotation ID": 1452390346,
            "Study Type": null,
            "Study Cases": 48.0,
            "Study Controls": null,
            "Characteristics": "Outpatient youth aged 12-17 years who had at least one first-degree relative with bipolar I disorder; dose-normalized AUC0-24",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.025",
            "Ratio Stat Type": null,
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Multiple groups, Non-Hispanic Caucasian n=33, Hispanic Caucasian n=6, Black or African n = 6, Multiple or other n=6",
            "Variant Annotation ID_norm": "1452390346"
        }
    ],
    "var_drug_ann": [
        {
            "Variant Annotation ID": 1452390346,
            "Variant/Haplotypes": "CYP2C19 intermediate metabolizer",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "Metabolism/PK",
            "Significance": "yes",
            "Notes": "CPIC guidelines used to assign CYP2C19  metabolizer phenotypes based on CYP2C19: *1, *2,*3, *4, *5, *6, *7, *8, *17. \"CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0-24 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram (Fig. 1).\" \"CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs).",
            "Sentence": "CYP2C19 intermediate metabolizer is associated with increased dose-adjusted trough concentrations of escitalopram in children with Depression or Anxiety Disorders as compared to CYP2C19 normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "dose-adjusted trough concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Other:Depression, Other:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "or",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "PMID_norm": "38377518",
            "Variant Annotation ID_norm": "1452390346"
        }
    ],
    "var_pheno_ann": [
        {
            "Variant Annotation ID": 1452390389,
            "Variant/Haplotypes": "CYP2D6 poor metabolizer",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "Toxicity",
            "Significance": "yes",
            "Notes": "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (p = 0.015; Fig. 2), but not with other TEASAP subscales\" \"participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).\" \"CYP2D6 metabolizer phenotypes were predominantly normal (NM n = 43) or intermediate (IM n = 15), with few ultrarapid (UM n = 2) or poor (PM n = 4) metabolizers. Two participants were excluded from CYP2D6-related analyses because genetic testing indicated gene duplications without revealing which allele was duplicated, thus precluding a definitive interpretation of CYP2D6 phenotype\" Alleles measured :CYP2D6: *1, *2, *2A, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *14, *15, *17, *41, gene duplication.",
            "Sentence": "CYP2D6 poor metabolizer is associated with increased likelihood of Psychomotor Agitation, Hyperkinesis or Impulse control disorder, unspecified when treated with escitalopram in children with Depression or Anxiety Disorders as compared to CYP2D6 normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "Side Effect:Psychomotor Agitation, Side Effect:Hyperkinesis, Side Effect:Impulse control disorder",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Other:Depression, Other:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "or",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "PMID_norm": "38377518",
            "Variant Annotation ID_norm": "1452390389"
        },
        {
            "Variant Annotation ID": 1452390301,
            "Variant/Haplotypes": "CYP2C19 intermediate metabolizer",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "CPIC guidelines used to assign CYP2C19  metabolizer phenotypes based on CYP2C19: *1, *2,*3, *4, *5, *6, *7, *8, *17. \"Slower CYP2C19 metabolizers tended to have greater TEASAP \"self-injury, suicidality, and harm to others\" subscale scores (F = 2.32, df = 2, p = 0.09), though CYP2C19 phenotype was not associated with increases in other TEASAP subscales scores\" \"CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs).",
            "Sentence": "CYP2C19 intermediate metabolizer is associated with increased likelihood of suicidal ideation, adverse events or deliberate self-harm when treated with escitalopram in children with Depression or Anxiety Disorders as compared to CYP2C19 normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Other:Depression, Other:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "or",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "PMID_norm": "38377518",
            "Variant Annotation ID_norm": "1452390301"
        },
        {
            "Variant Annotation ID": 1452390352,
            "Variant/Haplotypes": "rs6311",
            "Gene": "HTR2A",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "Toxicity",
            "Significance": "yes",
            "Notes": "Participants with HTR2A A/A or A/G genotypes had a greater increase in TEASAP \"Self-injury, Suicidality, and Harm to Others\" subscale scores relative to those with HTR2A G/G genotypes (p = 0.017)\" Alleles complemented.",
            "Sentence": "Genotypes CT + TT (assigned as intermediate metabolizer phenotype) is associated with increased likelihood of suicidal ideation, adverse events or deliberate self-harm when treated with escitalopram in children with Depression or Anxiety Disorders as compared to genotype CC (assigned as normal metabolizer phenotype) .",
            "Alleles": "CT + TT",
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Other:Depression, Other:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "or",
            "Comparison Allele(s) or Genotype(s)": "CC",
            "Comparison Metabolizer types": "normal metabolizer",
            "PMID_norm": "38377518",
            "Variant Annotation ID_norm": "1452390352"
        }
    ],
    "var_fa_ann": []
}